Edwards Lifesciences (NYSE: EW) has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock’s setup doesn’t necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Read the full article on Benzinga for deeper insights into the Adhishthana Cycle, the stock’s recent trajectory, and expert commentary.
